Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Health, Siemens Healthineers Partner to Promote Lung Cancer Molecular Testing in China

NEW YORK – Beijing-based Genetron Health said Thursday that it has entered a strategic partnership with Siemens Healthineers aimed at broadening the use of Genetron’s S5 sequencing platform and 8-gene lung cancer IVD assay in Chinese hospitals, providing non-small cell lung cancer patients with personalized diagnosis and treatment guidance.

The companies also plan to work together to help standardize cancer molecular testing practices in hospitals in China.

According to Genetron, lung cancer has the highest morbidity and mortality of all cancer types in China, with 787,000 cases of lung cancer diagnosed and about 631,000 deaths from the disease per year. In the US, the National Comprehensive Cancer Network recommends that molecular testing of lung cancer-related genes be used to guide targeted therapies for NSCLC patients.

"To help Chinese cancer patients access quality care, we are not only introducing cutting-edge testing analyzers and reagents to China but are also working with local innovators to offer personalized diagnostics … [and] we are excited to forge a strategic partnership with Genetron Health, an industry leading precision oncology platform company," Guo Yiming, VP of laboratory diagnostics at Siemens Healthineers Greater China, said in a statement.

Financial terms of the deal were not disclosed.